​

Rapport Therapeutics (RAPP) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

RAPP Stock Forecast

Rapport Therapeutics (RAPP) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $62.80, with a high of $75.00 and a low of $52.00. This represents a 43.08% increase from the last price of $43.89.

$15 $27 $39 $51 $63 $75 High: $75 Avg: $62.8 Low: $52 Last Closed Price: $43.89

RAPP Stock Rating

Rapport Therapeutics stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 5 Strong Sell Sell Hold Buy Strong Buy

RAPP Price Target Upside V Benchmarks

TypeNameUpside
StockRapport Therapeutics43.08%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts2311
Avg Price Target$70.50$64.33$55.00
Last Closing Price$43.89$43.89$43.89
Upside/Downside60.63%46.57%25.31%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 26112---13
Aug, 26112---13
Jul, 26111---12
Jun, 26110---11
May, 26110---11
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 17, 2026Tiago FauthRaymond James$75.00$47.4258.16%70.88%
Aug 12, 2026Douglas TsaoH.C. Wainwright$66.00$47.4239.18%50.38%
Jun 24, 2026Leerink Partners$52.00$38.8833.74%18.48%
May 21, 2026BTIG$65.00$35.7281.97%48.10%
May 18, 2026Truist Financial$56.00$35.1859.18%27.59%
Apr 10, 2026Tiago FauthRaymond James$66.00$34.1293.43%50.38%
Mar 09, 2026Kambiz YazdiBTIG$47.00$29.9756.82%7.09%
Feb 02, 2026Benjamin BurnettWells Fargo$43.00$26.6161.59%-2.03%
Dec 19, 2025Wells Fargo$51.00$29.6472.06%16.20%
Dec 09, 2025Douglas TsaoH.C. Wainwright$40.00$30.1632.63%-8.86%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 17, 2026UBSStrong BuyStrong Buyhold
Aug 12, 2026H.C. WainwrightBuyBuyhold
Jul 28, 2026William BlairOutperforminitialise
Jun 02, 2026CitigroupMarket OutperformMarket Outperformhold
May 21, 2026BTIGBuyBuyhold
Apr 10, 2026Raymond JamesStrong Buyinitialise
Mar 10, 2026CitigroupMarket OutperformMarket Outperformhold
Mar 09, 2026BTIGBuyBuyhold
Mar 09, 2026Cowen & Co.BuyBuyhold
Feb 02, 2026Wells FargoOverweightinitialise

Financial Forecast

EPS Forecast

Dec 24 Dec 25
Dec 24Dec 25
Reported$-0.38$-2.86
Avg Forecast$-3.65$-3.37
High Forecast$-3.29$-3.12
Low Forecast$-3.87$-3.70
Surprise %-89.59%-15.13%

Revenue Forecast

Dec 24 Dec 25
Dec 24Dec 25
Reported--
Avg Forecast--
High Forecast--
Low Forecast--
Surprise %--

Net Income Forecast

$-650M $-530M $-410M $-290M $-170M $-50M Dec 24 Dec 25
Dec 24Dec 25
Reported$-78.31M$-111.48M
Avg Forecast$-599.89M$-553.87M
High Forecast$-540.72M$-512.78M
Low Forecast$-636.05M$-608.11M
Surprise %-86.95%-79.87%

RAPP Forecast FAQ

Is Rapport Therapeutics stock a buy?

Rapport Therapeutics stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Rapport Therapeutics is a favorable investment for most analysts.

What is Rapport Therapeutics's price target?

Rapport Therapeutics's price target, set by 5 Wall Street analysts, averages $62.8 over the next 12 months. The price target range spans from $52 at the low end to $75 at the high end, suggesting a potential 43.08% change from the previous closing price of $43.89.

How does Rapport Therapeutics stock forecast compare to its benchmarks?

Rapport Therapeutics's stock forecast shows a 43.08% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Rapport Therapeutics over the past three months?

  • September 2026: 7.69% Strong Buy, 92.31% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 7.69% Strong Buy, 92.31% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 8.33% Strong Buy, 91.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.